Page last updated: 2024-12-06

p297

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	68761
SCHEMBL ID	3154425
MeSH ID	M0064979

Synonyms (19)

Synonym
P297 ,
3-[acetyl(methyl)amino]-n-(2-hydroxyethyl)-2,4,6-triiodo-5-[[(2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]benzamide
56562-79-9
ioglunidum [inn-latin]
3'-((2-hydroxyethyl)carbamoyl)-2',4',6'-triiodo-5'-(n-methylacetamido-d-glucoanilide
p-297
n-(3-(acetylmethylamino)-5-(((2-hydroxyethyl)amino)carbonyl)-2,4,6-triiodophenyl)-d-gluconamide
ioglunida
v4xu46crkn ,
unii-v4xu46crkn
p 297
ioglunida [inn-spanish]
ioglunidum
ioglunide [inn]
2,4,6-triiodo-3-(n-hydroxyethylcarbamyl)-5-(n-methylacetamido)-n-gluconylaminobenzene
3'-((2-hydroxyethyl)carbamoyl)-2',4',6'-triiodo-5'-(n-methylacetamido)-d-glucoanilide
SCHEMBL3154425
Q27291534
DTXSID401024027

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (16.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	5 (83.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	33.18 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	38.53 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (33.18)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	1.95	1	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	1.95	1	organic molecular entity
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	1.95	1	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
metrizamide Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.	1.95	1	amino sugar

Condition	Relationship Strength	Studies
Apoplexy [description not available]	2.6	1
Acute Ischemic Stroke [description not available]	2.6	1
Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.	2.6	1
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.6	1
Herpes Simplex Virus Infection [description not available]	2.6	1
Libman-Sacks Disease [description not available]	2.6	1
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	2.6	1
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	2.6	1
Greater Tuberosity Fractures [description not available]	2.6	1
Humeral Fractures Fractures of the HUMERUS.	2.6	1
Body Weight, Fetal [description not available]	2.6	1
Fetal Growth Restriction [description not available]	2.6	1
Fetal Growth Retardation Failure of a FETUS to attain expected GROWTH.	2.6	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.6	1
Absence Seizure [description not available]	1.95	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	1.95	1

chemdatabank.com